drugset / Trial / NCT04339426
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
Timeline
- Start
- 2020-04-20
- Primary completion
- 2022-02-11
- Completion
- 2022-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atovaquone | Small molecule | 750 mg | Oral |
| Subject | Azithromycin | Small molecule | 250 mg | Oral |